300326 凯利泰
已收盘 11-22 15:00:00
资讯
新帖
简况
凯利泰(300326)11月11日主力资金净买入3254.82万元
证券之星 · 11-12
凯利泰(300326)11月11日主力资金净买入3254.82万元
图解凯利泰三季报:第三季度单季净利润同比增78.69%
证券之星 · 10-24
图解凯利泰三季报:第三季度单季净利润同比增78.69%
凯利泰(300326.SZ)发布前三季度业绩,净利润5606.58万元,同比下降56.59%
智通财经 · 10-23
凯利泰(300326.SZ)发布前三季度业绩,净利润5606.58万元,同比下降56.59%
凯利泰最新公告:第三季度净利润2582.78万元 同比增长78.69%
证券之星 · 10-23
凯利泰最新公告:第三季度净利润2582.78万元 同比增长78.69%
凯利泰:融资余额2.66亿元,创近一年新低(09-10)
东方财富 · 09-11
凯利泰:融资余额2.66亿元,创近一年新低(09-10)
凯利泰:将于9月13日举行2024年第一次临时股东大会
中国财富通 · 09-10
凯利泰:将于9月13日举行2024年第一次临时股东大会
图解凯利泰中报:第二季度单季净利润同比减51.37%
证券之星 · 08-28
图解凯利泰中报:第二季度单季净利润同比减51.37%
凯利泰(300326.SZ)发布上半年业绩,净利润3023.8万元,同比下降73.64%
智通财经 · 08-27
凯利泰(300326.SZ)发布上半年业绩,净利润3023.8万元,同比下降73.64%
凯利泰(300326)8月13日主力资金净卖出676.39万元
证券之星 · 08-14
凯利泰(300326)8月13日主力资金净卖出676.39万元
凯利泰(300326)8月9日主力资金净买入1415.63万元
证券之星 · 08-12
凯利泰(300326)8月9日主力资金净买入1415.63万元
A股医疗器械板块开盘活跃,正海生物、奥精医疗涨停,大博医疗封板,凯利泰、威高骨科涨超10%。
美港电讯 · 08-09
A股医疗器械板块开盘活跃,正海生物、奥精医疗涨停,大博医疗封板,凯利泰、威高骨科涨超10%。
凯利泰(300326)7月30日主力资金净买入449.93万元
证券之星 · 07-31
凯利泰(300326)7月30日主力资金净买入449.93万元
上海椎元医学最近完成了一笔数千万元的天使轮融资。上海凯利泰医疗和张科禾苗基金作为领投方,华医资本作为跟投方参与了这次融资。
华尔街见闻 · 07-15
上海椎元医学最近完成了一笔数千万元的天使轮融资。上海凯利泰医疗和张科禾苗基金作为领投方,华医资本作为跟投方参与了这次融资。
椎元医学公布天使轮融资,融资额数千万人民币,投资方为凯利泰、张科禾苗基金等
证券之星 · 07-15
椎元医学公布天使轮融资,融资额数千万人民币,投资方为凯利泰、张科禾苗基金等
凯利泰(300326.SZ)2023年年度权益分派:每10股派0.6元 7月15日股权登记
智通财经网 · 07-08
凯利泰(300326.SZ)2023年年度权益分派:每10股派0.6元 7月15日股权登记
【凯利泰(300326.SZ)2023年年度权益分派:每10股派0.6元 7月15日股权登记】智通财经APP讯,凯利泰(300326.
智通财经 · 07-08
【凯利泰(300326.SZ)2023年年度权益分派:每10股派0.6元 7月15日股权登记】智通财经APP讯,凯利泰(300326.
凯利泰:公司目前暂时没有智能制造机器人、组织工程方面的业务
证券之星 · 06-26
凯利泰:公司目前暂时没有智能制造机器人、组织工程方面的业务
暂无数据
公司概况
公司名称:
上海凯利泰医疗科技股份有限公司
所属行业:
专用设备制造业
上市日期:
2012-06-13
主营业务:
上海凯利泰医疗科技股份有限公司主要从事椎体成形微创介入手术系统的研发、生产和销售,产品主要用于因骨质疏松导致的椎体压缩性骨折的临床微创手术治疗,具体包括经皮椎体成形(PVP)手术系统和经皮球囊扩张椎体后凸成形(PKP)手术系统。公司产品属于生物和新医药领域中重点支持的先进医疗设备、医用材料等生物医学工程产品,所属细分行业为骨科脊柱类微创介入医疗器械行业。公司自成立以来,一直致力于为骨质疏松导致的椎体压缩性骨折患者提供优质临床治疗方案,通过不断努力,公司率先在国内实现了顺应性椎体扩张球囊导管的国产化,打破了跨国公司的产品技术垄断,并大大的降低了产品价格,使更多的患者受益.目前,公司产品质量和稳定性已达到国际先进水平,产品覆盖了国内500多家二级以上医院并出口至欧洲、美洲等国家和地区,使超过数万名患者摆脱了病患的痛苦.公司能够在国内外椎体成形微创介入手术器械领域和跨国企业直接竞争,并且已经在国内市场建立了领先的市场地位。本公司依托不断加强的公司研发团队,瞄准骨科微创领域的发展趋势,坚持产品的滚动开发,并逐步实现了产品从技术跟随到技术创新和领先的身份转换。目前公司拥有国家药监局颁发的三类医疗器械产品注册证2项,拥有上海市药监局颁发的二类医疗器械产品注册证7项,一类医疗器械产品注册证2项,拥有国家批准的专利14项。
发行价格:
29.09
{"stockData":{"symbol":"300326","market":"SZ","secType":"STK","nameCN":"凯利泰","latestPrice":6.05,"timestamp":1732259010000,"preClose":6.1,"halted":0,"volume":24458400,"delay":0,"floatShares":717000000,"shares":717000000,"eps":0.055,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.05,"latestTime":"11-22 15:00:00","open":6.09,"high":6.31,"low":6.03,"amount":151000000,"amplitude":0.0459,"askPrice":6.06,"askSize":116,"bidPrice":6.05,"bidSize":452,"shortable":0,"etf":0,"ttmEps":0.055,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":6.1,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":6.71,"lowLimit":5.49,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":717026333,"pbRate":1.53,"roa":"--","roe":"1.94%","epsLYR":0.157,"committee":0.290338,"marketValue":4338000000,"floatMarketCap":4335000000,"peRate":110.000001,"changeRate":-0.0082,"turnoverRate":0.0341,"status":1},"requestUrl":"/m/hq/s/300326/tweets","defaultTab":"tweets","newsList":[{"id":"2482949837","title":"凯利泰(300326)11月11日主力资金净买入3254.82万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482949837","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482949837?lang=zh_cn&edition=full","pubTime":"2024-11-12 09:15","pubTimestamp":1731374138,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月11日收盘,凯利泰报收于6.32元,上涨6.94%,换手率4.54%,成交量32.56万手,成交额2.01亿元。近5日资金流向一览见下表:凯利泰融资融券信息显示,融资方面,当日融资买入2370.23万元,融资偿还1534.9万元,融资净买入835.33万元,连续3日净买入累计1505.66万元。凯利泰主营业务:骨科植入医疗器械的生产、研发、销售及服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200007625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300326","BK0251"],"gpt_icon":0},{"id":"2477559055","title":"图解凯利泰三季报:第三季度单季净利润同比增78.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477559055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477559055?lang=zh_cn&edition=full","pubTime":"2024-10-24 00:35","pubTimestamp":1729701346,"startTime":"0","endTime":"0","summary":"证券之星消息,凯利泰2024年三季报显示,公司主营收入7.5亿元,同比上升1.86%;归母净利润5606.58万元,同比下降56.59%;扣非净利润4413.74万元,同比下降45.67%;其中2024年第三季度,公司单季度主营收入2.74亿元,同比上升28.29%;单季度归母净利润2582.78万元,同比上升78.69%;单季度扣非净利润1921.25万元,同比上升62.25%;负债率13.0%,投资收益-623.74万元,财务费用-271.94万元,毛利率49.05%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400000246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300326"],"gpt_icon":0},{"id":"2477302966","title":"凯利泰(300326.SZ)发布前三季度业绩,净利润5606.58万元,同比下降56.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477302966","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477302966?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:44","pubTimestamp":1729680269,"startTime":"0","endTime":"0","summary":"智通财经APP讯,凯利泰(300326.SZ)发布2024年三季度报告,前三季度,公司实现营业收入7.5亿元,同比增长1.86%。归属于上市公司股东的净利润5606.58万元,同比下降56.59%。归属于上市公司股东的扣除非经常性损益的净利润4413.74万元,同比下降45.67%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1198199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300326"],"gpt_icon":0},{"id":"2477304330","title":"凯利泰最新公告:第三季度净利润2582.78万元 同比增长78.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477304330","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477304330?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:20","pubTimestamp":1729678836,"startTime":"0","endTime":"0","summary":"凯利泰发布2024年第三季度报告,报告期内公司实现营业收入2.74亿元,同比增长28.29%;归属于上市公司股东的净利润为2582.78万元,同比增长78.69%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300031266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300326"],"gpt_icon":0},{"id":"2466445898","title":"凯利泰:融资余额2.66亿元,创近一年新低(09-10)","url":"https://stock-news.laohu8.com/highlight/detail?id=2466445898","media":"东方财富","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466445898?lang=zh_cn&edition=full","pubTime":"2024-09-11 09:13","pubTimestamp":1726017180,"startTime":"0","endTime":"0","summary":"凯利泰融资融券信息显示,2024年9月10日融资净偿还157.64万元;融资余额2.66亿元,创近一年新低,较前一日下降0.59%。融资方面,当日融资买入75.45万元,融资偿还233.09万元,融资净偿还157.64万元,连续5日净偿还累计641.67万元。融券方面,融券卖出0股,融券偿还0股,融券余量15.93万股,融券余额66.75万元。融资融券余额合计2.66亿元。凯利泰融资融券交易明细(09-10)凯利泰历史融资融券数据一览免责声明:本文基于AI生产,仅供参考,不构成任何投资建议,据此操作风险自担。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-09-11/doc-incntvry4305671.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-09-11/doc-incntvry4305671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300326","BK0251"],"gpt_icon":0},{"id":"2466355104","title":"凯利泰:将于9月13日举行2024年第一次临时股东大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2466355104","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466355104?lang=zh_cn&edition=full","pubTime":"2024-09-10 15:07","pubTimestamp":1725952031,"startTime":"0","endTime":"0","summary":"中国财富通9月10日 - 凯利泰(300326)公告称,公司将于9月13日(星期五)召开2024年第一次临时股东大会。本次股东大会采用现场投票、网络投票相结合的方式召开,现场会议时间为当天14时50分,网络投票时间为9月13日。届时将审议关于购买董监高责任险的议案、关于公司聘任财务审计机构的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=C9TXCGhGCCI%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300326","BK0251"],"gpt_icon":0},{"id":"2462114511","title":"图解凯利泰中报:第二季度单季净利润同比减51.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462114511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462114511?lang=zh_cn&edition=full","pubTime":"2024-08-28 01:46","pubTimestamp":1724780811,"startTime":"0","endTime":"0","summary":"证券之星消息,凯利泰2024年中报显示,公司主营收入4.76亿元,同比下降8.96%;归母净利润3023.8万元,同比下降73.64%;扣非净利润2492.49万元,同比下降64.08%;其中2024年第二季度,公司单季度主营收入2.3亿元,同比上升0.61%;单季度归母净利润1936.16万元,同比下降51.37%;单季度扣非净利润1661.33万元,同比下降27.43%;负债率11.0%,投资收益-435.14万元,财务费用-283.24万元,毛利率50.99%。财报数据概要请见下图: 以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082800002102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300326"],"gpt_icon":0},{"id":"2462161977","title":"凯利泰(300326.SZ)发布上半年业绩,净利润3023.8万元,同比下降73.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462161977","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462161977?lang=zh_cn&edition=full","pubTime":"2024-08-27 20:11","pubTimestamp":1724760710,"startTime":"0","endTime":"0","summary":"智通财经APP讯,凯利泰(300326.SZ)发布2024年半年度报告,公司营业收入4.76亿元,同比下降8.96%;归属于上市公司股东的净利润3023.8万元,同比下降73.64%;归属于上市公司股东的扣除非经常性损益的净利润2492.49万元,同比下降64.08%;基本每股收益0.0422元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1172216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300326"],"gpt_icon":0},{"id":"2459161041","title":"凯利泰(300326)8月13日主力资金净卖出676.39万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459161041","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459161041?lang=zh_cn&edition=full","pubTime":"2024-08-14 09:27","pubTimestamp":1723598856,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月13日收盘,凯利泰报收于4.05元,下跌1.22%,换手率1.82%,成交量13.05万手,成交额5247.75万元。近5日资金流向一览见下表:凯利泰融资融券信息显示,融资方面,当日融资买入363.97万元,融资偿还621.13万元,融资净偿还257.17万元。凯利泰主营业务:骨科植入医疗器械的生产、研发、销售及服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081400016625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300326","BK0251"],"gpt_icon":0},{"id":"2458481406","title":"凯利泰(300326)8月9日主力资金净买入1415.63万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458481406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458481406?lang=zh_cn&edition=full","pubTime":"2024-08-12 09:11","pubTimestamp":1723425098,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月9日收盘,凯利泰报收于4.3元,上涨4.62%,换手率6.27%,成交量44.94万手,成交额2.07亿元。近5日资金流向一览见下表:凯利泰融资融券信息显示,融资方面,当日融资买入1490.54万元,融资偿还1419.15万元,融资净买入71.39万元。凯利泰主营业务:骨科植入医疗器械的生产、研发、销售及服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081200002357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300326"],"gpt_icon":0},{"id":"2458309716","title":"A股医疗器械板块开盘活跃,正海生物、奥精医疗涨停,大博医疗封板,凯利泰、威高骨科涨超10%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2458309716","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458309716?lang=zh_cn&edition=full","pubTime":"2024-08-09 09:29","pubTimestamp":1723166989,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["300326","BK1100","BK1574","09997","300653","BK1222","BK0251","159982","688613","BK0046","09996","159883","BK1583","399300","688161","002901"],"gpt_icon":0},{"id":"2455108079","title":"凯利泰(300326)7月30日主力资金净买入449.93万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2455108079","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455108079?lang=zh_cn&edition=full","pubTime":"2024-07-31 09:14","pubTimestamp":1722388486,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月30日收盘,凯利泰报收于3.89元,上涨3.18%,换手率1.02%,成交量7.32万手,成交额2816.23万元。近5日资金流向一览见下表:凯利泰融资融券信息显示,融资方面,当日融资买入279.56万元,融资偿还283.51万元,融资净偿还3.95万元。融券方面,融券卖出0.0股,融券偿还3.69万股,融券余量18.05万股,融券余额70.21万元。凯利泰主营业务:骨科植入医疗器械的生产、研发、销售及服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100015878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300326","BK0251"],"gpt_icon":0},{"id":"2451621194","title":"上海椎元医学最近完成了一笔数千万元的天使轮融资。上海凯利泰医疗和张科禾苗基金作为领投方,华医资本作为跟投方参与了这次融资。","url":"https://stock-news.laohu8.com/highlight/detail?id=2451621194","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451621194?lang=zh_cn&edition=full","pubTime":"2024-07-15 23:06","pubTimestamp":1721056019,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK0251","159891","300326"],"gpt_icon":0},{"id":"2451964567","title":"椎元医学公布天使轮融资,融资额数千万人民币,投资方为凯利泰、张科禾苗基金等","url":"https://stock-news.laohu8.com/highlight/detail?id=2451964567","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451964567?lang=zh_cn&edition=full","pubTime":"2024-07-15 19:28","pubTimestamp":1721042923,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP于7月11日公布的信息整理,椎元医学技术(上海)有限公司公布天使轮融资,融资额数千万人民币,参与投资的机构包括凯利泰,张科禾苗基金,华医资本。椎元医学坐落于张江科学城,是基于成纤维细胞开发创新细胞疗法的初创企业,专注未满足的临床需求,给患者带来福祉。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500026221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300326","BK0251"],"gpt_icon":0},{"id":"2449793477","title":"凯利泰(300326.SZ)2023年年度权益分派:每10股派0.6元 7月15日股权登记","url":"https://stock-news.laohu8.com/highlight/detail?id=2449793477","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449793477?lang=zh_cn&edition=full","pubTime":"2024-07-08 19:36","pubTimestamp":1720438588,"startTime":"0","endTime":"0","summary":"凯利泰(300326.SZ)发布公告,公司2023年年度权益分派方案为:以公司现有...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astock/7.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/7.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1147214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0251","300326"],"gpt_icon":0},{"id":"2449793107","title":"【凯利泰(300326.SZ)2023年年度权益分派:每10股派0.6元 7月15日股权登记】智通财经APP讯,凯利泰(300326.","url":"https://stock-news.laohu8.com/highlight/detail?id=2449793107","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449793107?lang=zh_cn&edition=full","pubTime":"2024-07-08 19:36","pubTimestamp":1720438588,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0251","300326"],"gpt_icon":0},{"id":"2446504143","title":"凯利泰:公司目前暂时没有智能制造机器人、组织工程方面的业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2446504143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446504143?lang=zh_cn&edition=full","pubTime":"2024-06-26 18:02","pubTimestamp":1719396128,"startTime":"0","endTime":"0","summary":"证券之星消息,凯利泰06月26日在投资者关系平台上答复投资者关心的问题。谢谢凯利泰董秘:您好,感谢您对公司的关注与支持,公司目前暂时没有智能制造机器人、组织工程方面的业务,谢谢。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600036539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0089","BK0251","BK0073","300024","BK0028","BK0259","BK0196","BK0005","BK0188","BK0130","BK0122","159526","BK0061","300326"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2012-06-13","address":"上海市浦东新区张江高科技园东区瑞庆路528号23幢","stockEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.1458},{"period":"3month","weight":0.5796},{"period":"6month","weight":0.3305},{"period":"1year","weight":-0.1104},{"period":"ytd","weight":-0.0289}],"companyName":"上海凯利泰医疗科技股份有限公司","boardCode":"AI0035","perCapita":"15213股","boardName":"专用设备制造业","registeredCapital":"71702万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":" 上海凯利泰医疗科技股份有限公司主要从事椎体成形微创介入手术系统的研发、生产和销售,产品主要用于因骨质疏松导致的椎体压缩性骨折的临床微创手术治疗,具体包括经皮椎体成形(PVP)手术系统和经皮球囊扩张椎体后凸成形(PKP)手术系统。公司产品属于生物和新医药领域中重点支持的先进医疗设备、医用材料等生物医学工程产品,所属细分行业为骨科脊柱类微创介入医疗器械行业。公司自成立以来,一直致力于为骨质疏松导致的椎体压缩性骨折患者提供优质临床治疗方案,通过不断努力,公司率先在国内实现了顺应性椎体扩张球囊导管的国产化,打破了跨国公司的产品技术垄断,并大大的降低了产品价格,使更多的患者受益.目前,公司产品质量和稳定性已达到国际先进水平,产品覆盖了国内500多家二级以上医院并出口至欧洲、美洲等国家和地区,使超过数万名患者摆脱了病患的痛苦.公司能够在国内外椎体成形微创介入手术器械领域和跨国企业直接竞争,并且已经在国内市场建立了领先的市场地位。本公司依托不断加强的公司研发团队,瞄准骨科微创领域的发展趋势,坚持产品的滚动开发,并逐步实现了产品从技术跟随到技术创新和领先的身份转换。目前公司拥有国家药监局颁发的三类医疗器械产品注册证2项,拥有上海市药监局颁发的二类医疗器械产品注册证7项,一类医疗器械产品注册证2项,拥有国家批准的专利14项。","serverTime":1732490735123,"listedPrice":29.09,"stockholders":"47103人(较上一季度减少1.74%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯利泰(300326)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯利泰(300326)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯利泰,300326,凯利泰股票,凯利泰股票老虎,凯利泰股票老虎国际,凯利泰行情,凯利泰股票行情,凯利泰股价,凯利泰股市,凯利泰股票价格,凯利泰股票交易,凯利泰股票购买,凯利泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯利泰(300326)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯利泰(300326)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}